Tag
Pranav Amin
2 articles
Alembic Pharma Expands DifGen Collaboration for US Complex Generics
Alembic Pharmaceuticals expands strategic collaboration with DifGen Pharmaceuticals to commercialize a portfolio of 20+ complex generics in the US market.
The portfolio targets a $5 billion reference
Alembic Pharmaceuticals Q2 PAT Surges 81% YoY
Alembic Pharmaceuticals reported unaudited Q2 FY27 results with revenue growth of 36% YoY to ₹2,603 Cr.
Profit After Tax surged 81% YoY to ₹335 Cr, driven by strong US formulations growth of 77%.
All